Thrombus/thrombogenesis inhibitors comprising as the active ingredient aminoalkoxybibenzyls represented by the following general formula (1), pharmaceutically acceptable salts thereof or solvates of the same: (1) wherein R<sp>1</sp>, R<sp>2</sp> and R<sp>3</sp> represent each hydrogen, etc.; R<sp>4</sp> represents −N(R<sp>5</sp>)(R<sp>6</sp>); and m is an integer of from 0 to 5. The above drugs are particularly efficacious for inhibiting thrombus/thrombogenesis in ischemic cerebrovascular failures selected from transient cerebral ischemic attack and cerebral infarction.
